Abstract | OBJECTIVES: METHODS: A systematic literature search of major electronic databases was conducted. Meta-analysis of clinical efficacy as defined by the respective studies, all-cause discontinuation, adverse drug reactions (ADRs) with standardized mean difference (SMD) and risk ratios (RRs) and their 95% confidence intervals (CI) was conducted using random-effects model. Quality assessment was performed with the Jadad scale and Cochrane risk of bias. RESULTS: Sixteen RCTs (n=1357) on minocycline (50-300 mg/day) for schizophrenia (13 RCTs, n=1196), bipolar depression (1 RCT, n=49), and MDD (2 RCTs, n=112) were analyzed separately by diagnosis. Twelve RCTs mentioned randomized allocation specifically; the weighted Jadad scores were 4.0. Adjunctive minocycline outperformed placebo in improving total psychopathology [SMD: -0.45 (95%CI: -0.73, -0.16), p=0.002; I2=77%], positive [SMD: -0.15 (95%CI: -0.28, -0.02), p=0.02; I2=0%], negative [SMD: -0.62 (95%CI: -0.95, -0.28), p=0.0003; I2=85%] and general psychopathology scores [SMD: -0.28 (95%CI: -0.53, -0.03), p=0.03; I2=59%] in schizophrenia. Minocycline showed no significant effect on depressive and manic symptoms in both bipolar depression and MDD. Minocycline caused significantly less headache (p=0.02, number-needed-to-harm=14, 95%CI=5-14) than placebo in schizophrenia. All-cause discontinuation and other ADRs were similar between minocycline and placebo in each diagnostic category. CONCLUSION: REVIEW REGISTRATION: PROSPERO: CRD42018102483.
|
Authors | Wei Zheng, Xiao-Min Zhu, Qing-E Zhang, Gen Cheng, Dong-Bin Cai, Jie He, Chee H Ng, Gabor S Ungvari, Xiao-Jiang Peng, Yu-Ping Ning, Yu-Tao Xiang |
Journal | Journal of psychopharmacology (Oxford, England)
(J Psychopharmacol)
Vol. 33
Issue 10
Pg. 1215-1226
(10 2019)
ISSN: 1461-7285 [Electronic] United States |
PMID | 31294649
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review)
|
Chemical References |
- Anti-Inflammatory Agents
- Minocycline
|
Topics |
- Anti-Inflammatory Agents
(adverse effects, pharmacology)
- Bipolar Disorder
(drug therapy)
- Depressive Disorder, Major
(drug therapy)
- Humans
- Minocycline
(adverse effects, pharmacology)
- Schizophrenia
(drug therapy)
|